Andrew Plump

President, Research & Development
Takeda Pharmaceutical Company Limited

Andrew Plump, M.D., Ph.D., is the president of Research & Development at Takeda Pharmaceutical Company Limited and serves as a member of the company’s board of directors. His career spans nearly 30 years in the pharmaceutical industry and academia and his experience encompasses early research through regulatory approval and patient access.

Dr. Plump oversees Takeda’s global R&D organization of more than 5,000 employees. Early in his tenure he orchestrated a multi-year strategic and cultural transformation that has resulted in a renewed focus on innovation, streamlined global footprint, prioritized therapeutic areas of focus, a rich network of partnerships and a modality-diverse portfolio of newly approved and promising late-stage development experimental therapies. He also championed efforts to build an exciting and sustainable early development and research pipeline, founded on strong translational science as well as platform capabilities in cell therapy, gene therapy and data sciences. Over the last several years, Dr. Plump has substantially increased the company’s investment in research and partnerships and the launch and growth of medicines that provide meaningful benefit to society.

Prior to Takeda, Dr. Plump served as head of Research & Translational Medicine, deputy to the president of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as worldwide cardiovascular (CV) research head at Merck.